Managing Obesity with Prescription Weight-Loss Drugs Nursing

How To Take A quiz?

Fill out all required information.
Carefully read the question.
Then choose the answer and click on it.
Correct/Incorrect response will be displayed.
Use "Next" button to go to the next question.
Score will be shown at the conclusion of the quiz.
Received Passing score - Great ! close the browser window
Received Failed score - Retake quiz until you pass

Ready? Let's click on "Start Quiz" button and get started !

Please enter Full Legal Name (First and Last Name) to be printed on the certificate.

1 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 1:

Which group has the highest prevalence of obesity?

A) Women, aged 18-22

B) Men, aged 60-75

C) Women, aged 40-59

D) Men aged 40-59

2 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 2:

A BMI of 34.5 falls within the classification of obesity.

A) True

B) False

3 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 3:

Which of the following would be appropriately indicated for initiating an FDA-approved prescription weight-loss drug?

A) Obesity (30.2 kg/m2), but lost 12 lbs in the last 2 months with beginning the Mediterranean diet and daily walking regimen.

B) Overweight (BMI = 29 kg/m2) with the presence of complications (type 2 diabetes mellitus and hypertension) and lifestyle modifications have had no clinical improvement in weight loss.

C) Overweight (BMI = 27 kg/m2) and lacks understanding of nutritional density in foods and physical activity.

D) Overweight (BMI = 28 kg/m2) and recovering from bulimia over the past year without professional nutritional or behavioral support.

4 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 4:

All of the following are approved for long-term use for chronic weight loss management, EXCEPT:

A) Orlistat

B) Semaglutide

C) Liraglutide

D) Phentermine

5 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 5:

Sympathomimetic Amines are contraindicated in individuals with hyperthyroidism.

A) True

B) False

6 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 6:

GLP-1 Receptor Agonists are effective in suppressing appetite and reducing weight. What mechanisms are involved?

A) Slowing of gastric emptying

B) Inhibiting inappropriate post-meal glucagon release

C) Promotes insulin release from the pancreas

D) All of the above

7 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 7:

Which of the following conditions would be contraindicated when using Liraglutide and Semaglutide?

A) History of medullary thyroid carcinoma (MTC)

B) Hypertension

C) High cholesterol and triglyceride levels

D) Osteoarthritis

8 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 8:

Which of the following can impact the absorption of orlistat if diarrhea occurs?

A) Fat-soluble vitamins (A, D, E, and K)

B) β-carotene

C) Oral contraceptives

D) All of the above

9 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 9:

Gastrointestinal lipases are essential in the absorption of long-chain triglycerides.

A) True

B) False

10 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 10:

Which patients would require close monitoring and additional education after starting Orlistat?

A) A patient on warfarin.

B) A patient who closely monitors their daily blood pressure.

C) A patient with a history of depression.

D) A patient that appropriately applies multiple forms of contraceptives.

11 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 11:

What are the essential clinical implications for Naltrexone / Bupropion, EXCEPT?

A) Gradual titration / slowly increasing to the therapeutic dose.

B) Advise to stop taking the medication if nausea is experienced immediately.

C) Avoiding this medication if uncontrolled hypertension or a history of seizures is present.

D) Do not begin medication during or within 14 days of taking monoamine oxidase inhibitors.

12 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 12:

Which of the following is NOT a contraindication for Phentermine/Topiramate combination therapy?

A) Pregnancy

B) Glaucoma

C) Insomnia

D) Hyperthyroidism

13 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 13:

GLP-1 is effective by:

A) Stimulating glucose-dependent insulin release from the pancreatic islets.

B) Slowing of gastric emptying.

C) Inhibiting inappropriate post-meal glucagon release.

D) All of the above

14 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 14:

GLP-1 receptor agonists should be discontinued if weight loss of at least 4% is not achieved after 16 weeks of therapy.

A) True

B) False

15 / 15

Managing Obesity with Prescription Weight-Loss Drugs

Question 15:

Orlistat was found to be the most effective medication for weight loss.

A) True

B) False

Your score is

Our Course Categories

Unlimited CEUs

Infection Control

Dental

Nursing

Pharmacy

Physical Therapy

Occupational Therapy

Massage Therapy

Rehab CE (🎥+PDF)

SLP & Audiology

Pharmacology CE

LCSWs/MFTs/LMHCs

Compliance

Tattoo/Body Art BBP

HIPAA Training

Biologix Solutions LLC